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This article summarizes current knowledge on the mutual position of surgical and
interventional treatment of patients with multivessel coronary artery disease. It focuses
on the possibilities of their combined use – so called hybrid myocardial revascularization.
The use of minimally invasive surgery combined with current technologies of coronary
interventions offers new opportunities, taking advantages of both procedures and
eliminating some of their disadvantages. This previously rarely used technique could
improve the clinical outcomes and treatment comfort in selected groups of patients.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Despite the fact that coronary artery disease is one of the
most studied diseases in history of medicine and that very
effective methods of treatment were developed, the treat-
ment strategy of multivessel coronary artery disease is still
controversial. Treatment options and their combinations
with continuing development of new techniques of surgical
revascularization and percutaneous coronary interventions
are in constant progress and the position of each method in
the therapeutic range keeps changing. Traditionally, clini-
cians see coronary artery bypass grafting (CABG) and percu-
taneous coronary intervention (PCI) as two parallel and
mutually exclusive options that can be offered to patients
with multivessel coronary artery disease. Both strategies
have obvious advantages but also disadvantages. Coronary
intervention, using stents, offers virtual painlessness, mini-
mal procedural risk at short-term hospitalization with early
mobilization and rapid return to normal life, but with some
risk of restenosis and higher risk of having another interven-
tion in the future. Surgical treatment offers uncompromising
possibilities of revascularization of all affected arteries with
the guarantee of unparalleled long-term patency of arterial
grafts at a price of higher perioperative morbidity and
mortality, longer hospitalization and slower return to routine
activities. However, the development gradually offers a
choice of mutual complementary use of both methods. The
trend in surgical area is to reduce the demands of the
procedure by introducing minimally invasive surgical techni-
ques and on the interventional side to increase the long-term
effectiveness of interventional procedures by using drug-
eluting stents (DES), which offer outcomes close to surgical
revascularization by venous grafts. The use of the best of
these separated worlds as a combination of minimally inva-
sive surgery and percutaneous coronary intervention (hybrid
techniques) offers new treatment strategies that can be
equally or even more effective than the existing ones; and
safe for the patient at the same time.2. Coronary artery bypass grafting versus PCI
– analysis of previous trials
The debate over the optimal treatment for patients with
multivessel coronary artery disease rages for many years
and continues until now. Its importance is enhanced by the
fact that the age and severity of comorbidities of the patients
with coronary artery disease is increasing and it correlates
with the increasing number of patients requiring revascular-
ization for multivessel coronary lesions [1]. Historically,
coronary artery bypass grafting was considered a first-line
treatment in patients with multivessel coronary artery dis-
ease and/or with lesion on left main coronary artery [2],
however, advances in PCI in last years have made this option
an attractive alternative of surgical treatment, especially after
the introduction of drug-eluting stents (DES). Meta-analysis
of 4 randomized trials that compared treatment by using
standard bare metal stents (BMS) with CABG in patients with
multivessel coronary artery disease in five years of follow-upshowed similar mortality rate and composite adverse events
(death, myocardial infarction and stroke) in both groups
(16.7% for PCI vs. 16.9% for CABG) and significantly higher
frequency of need for another revascularization in the inter-
ventionally treated group (29% vs. 7.9%) [3]. A much larger
meta-analysis, which included also trials with simple balloon
angioplasty (number of enrolled patients was nearly 10,000)
came to similar conclusion – both groups did not differ in
mortality, patients with CABG had more frequent periproce-
dural stroke and patients after PCI needed further revascu-
larization (absolute difference in risk after 5 years 33%) [4].
Analysis of individual data from 10 randomized trials (includ-
ing both trials with simple angioplasty and stent implanta-
tion, with a total of 7812 patients) also led to the same results,
median of follow- up was 5.9 years, where the difference in
total mortality was only 1% (15% CABG vs. 16% PCI) [5].
Development of drug eluting stents led to significant
decrease in number of restenoses and subsequent need of
revascularization after coronary intervention [6]. It implies
that when PCI is chosen as a treatment, drug-eluting stents
should be used. In case their use is not possible, some
cardiologists use it as an argument for surgical revasculariza-
tion. There is currently no randomized trial which compares
specifically conventional stents with drug-eluting stents in
patients with multivessel coronary disease. Comparable data
exist from trials ARTS I [2] and ARTS II, which compared
conventional bare metal stents and drug-eluting stents,
respectively, with surgical treatment in patients with 2–3
affected coronary arteries. There was no difference in mor-
tality between the group of patients treated with conven-
tional and drug-eluting stents after 5 years and as expected,
there was a significant decrease in revascularization need in
patients with drug-eluting stents (20% vs. 9%) [7]. Observa-
tional data from a large New York registry of 17,400 patients
with multivessel coronary artery disease show similar survi-
val after CABG and PCI at 18 months, whether there was a
double- or triple- vessel disease [8]. The only randomized
data comparing drug-eluting stents to CABG in multivessel
coronary artery disease come from the SYNTAX trial [9],
where 1800 patients with three- vessel disease and/or left
main coronary artery lesion were included. Combined inci-
dence of adverse events (death, myocardial infarction, stroke
and revascularization) after two years favoured CABG to PCI
(14.4% vs. 23.8%, po0.001) but the difference was largely due
to decreased number of subsequent revascularizations (7.5%
vs. 17.4%, po0.001). However, the myocardial infarction rate
was lower in patients after surgical procedure (2.8% vs. 6.1%,
po0.009) as well as number of deaths due to cardiac events
(2.3% vs. 4.5%; p¼0.05). On the other hand, the frequency of
stroke was significantly higher in the group with CABG. The
gap between these two groups grew larger with increasing
complexity of coronary artery lesions, evaluated by a new
scoring system – SYNTAX score. Patients in the lower per-
centile of Syntax score had similar outcomes in both groups;
the superiority of surgical treatment to interventional treat-
ment was evident with increasing value of the score. This
trend persisted even after 3 years [10].
Historically, surgical myocardial revascularization was con-
sidered more effective for patients with diabetes [11] in
terms of long-term mortality and this eventuality was also
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diabetes from 10 trials performed by Hlatky et al. [5]. So far,
the only randomized trial comparing specifically CABG to PCI
with stent implantation in patients with diabetes and multi-
vessel coronary artery lesions, including patients with con-
ventional, as well as drug-eluting stents, was terminated
prematurely for slow recruitment. There was no difference
in 1 year mortality or composite adverse events (death, MI,
stroke), however, patients in interventional group had again
increased number of subsequent revascularizations (9.9 vs 2%,
po0.001) and the difference was significant even in patients
with drug-eluting stents (7.3% vs. 2%, p¼0.013) [12]. Recently,
the group of diabetic patients in SYNTAX trial treated by
interventional therapy using drug-eluting stents also showed
higher incidence of subsequent revascularizations compared
to CABG (20.3 vs. 6.4%, po0,001) with similar mortality (that
was higher in comparison to patients without diabetes in
both revascularization strategies). The difference in mortality
was obvious in subgroup with very complex artery lesions –
high SYNTAX score value (13.5% vs. 4.1%, p¼0.04) [13]. The
final decision about relative merits of both approaches in
diabetic patients awaits the results of further randomized
trials. A group of patients with lesion on left main coronary
artery was considered for surgical treatment until now;
and it was also reflected in guidelines which classified PCI in
patients capable of surgical revascularization to the level of
evidence III [14]. However, many of these patients were treated
by angioplasty during last years [15]. Recent analysis of avail-
able data which showed that PCI may be an alternative
for surgical treatment for a significant proportion of patients
with left main coronary artery lesion [16] led to reassessment
of these guidelines and included PCI to the level of evidence II b
for those with suitable anatomy [17]. A large MAIN – COMPARE
registry, comparing CABG and PCI outcomes in patients with
stem lesion (2240 patients), showed quite consistently
similar risk profile of both methods in terms of mortality and
reinfarction after 5 years as above, but with higher percen-
tage of subsequent revascularization after PCI, while use of
drug-eluting stents significantly decreased number of reinter-
ventions [18]. The same conclusion was reached in a meta-
analysis of 3773 patients from different trials treated with both
procedures [19]. Patients with left main coronary artery
lesion in the SYNTAX study represent the largest cohort of
patients previously randomized between both types of treat-
ment (357 PCI, 348 CABG). After 2 years there was no difference
in overall adverse events (22.9% and 19.3%), mortality (5.6% vs.
6.2%), even in number of myocardial infarctions (5.5% vs. 4.1%).
Patients with percutaneous intervention had decreased rate of
strokes (0.9% vs. 3.7%, p¼0.01) but again more revasculariza-
tions (17.3 vs. 10.4%, p¼0.01). The resulting stratification
according to the gravity of coronary arteries lesions (SYNTAX
score) showed that in patients with lower scores (in first and
second tercile, i.e. up to 32), PCI may be even safer and as
effective as CABG [20], which would represent about 1/3 of all
patients with lesion of left main coronary artery, eventually
other coronary arteries.
Generally, it is possible to summarize that PCI and CABG in
patients with multivessel coronary artery disease have simi-
lar prognosis in terms of mortality and reinfarctions when
comparable level of revascularization is reached. Coronaryartery bypass grafting leads to better long-term relief of
symptoms which is reflected in decreased number of sub-
sequent revascularizations but at a price of higher incidence
of stroke and perioperative mortality. Coronary artery bypass
grafting may be a better alternative in terms of long-term
prognosis for patients with diabetes and with complex multi-
vessel coronary artery disease [4–6].3. Left anterior descending artery (LAD) in
myocardial revascularization
Prognostic significance of coronary artery bypass grafting is
connected to the revascularisation of left main or proximal
LAD lesions [21]. The left anterior descending artery is the
most important coronary artery as it supplies approximately
60% of the myocardium of the left ventricle [22]. Successful
revascularization of this artery is therefore a logical require-
ment for improving long term prognosis of patients [23,24].
Based on prior evidence, the optimal surgical revasculariza-
tion method for this artery is a bypass using the left internal
mammary artery – LIMA [25–27]. The LIMA graft has excellent
long term patency (up to 98% at 1 year, 95% at 10 years and
approximately 90% at 15 years or more) [28–33]. In the BARI
trial, the superiority of CABG to PCI in patients with diabetes
was found only in patients in whom LAD was revascularized
with LIMA. Patients with venous LAD grafts had the same
prognosis as patients treated with PCI [11]. Grafting LIMA on
LAD has therefore become the standard form of surgical
revascularization. Direct comparison of the efficacy of revas-
cularization of isolated lesions of LAD between LIMA grafts
and coronary angioplasty has been done in a number of
smaller trials, most of which used standard bare metal
stents. Metanalysis of these trials has shown similar inci-
dence of death and reinfarction with a significantly higher
number of follow up revascularizations after PCI [34–36], even
in the long term perspective of 10 years [37]. Only two
randomized trials have compared mini invasive LIMA–LAD
grafts with implantation of drug eluting stents. In both trials,
these two methods had similar results regarding occurrence
of death, reinfarction, and follow up revascularization in the
short term follow up of 6–12 months [38,39]. Long term
randomized comparison is missing, but midterm follow up
(median of 2 years) of comparable groups of patients, treated
with both methods, has shown significantly higher recur-
rence of angina in patients who have undergone implanta-
tion of drug eluting stents [40,41]. Even with the progress that
drug eluting stents represent, it would seem that LIMA
remains to be the most effective method of LAD revascular-
ization. The high long- term patency of the LIMA graft
protects the key LAD region against clinical consequences
of atherosclerosis progression on the native vessel [42] (even
though grafting has been shown to accelerate the athero-
sclerotic process of the artery prior to the graft site [43]). On
the other hand, coronary intervention using stents only
treats a localized lesion in a relatively small part of the artery
and has no long term protective effect on other segments of
the artery.
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revascularization of LAD
The invasive character of standard surgical approach to
aortocoronary bypass is related mainly with the need of a
sternotomy, extracorporeal blood circulation and manipula-
tion with the heart and aorta during the procedure. The
sternotomy is associated with prolonged rehabilitation
and possible infectious complications at the sternotomy
site [44]. Extracorporeal blood supply causes a strong sys-
temic inflammatory response [45], which, together with
coagulation activation and platelet destruction [46], promotes
organ dysfunction and post-operative blood loss and there-
fore increased perioperative morbidity [47]. The manipulation
with the heart and ascending aorta together with extracor-
poreal circulation are associated mainly with a risk of devel-
oping perioperative stroke and postoperative cognitive
dysfunction [48]. The introduction of operative techniques
without extracorporeal circulation (off-pump coronary artery
bypass – OPCAB) has led to a significant decrease of perio-
perative morbidity with equal long term results in mortality
and adverse events [49].
Limited lateral thoracotomy in the 4–5th intercostal space
is an alternative surgical access that allows LAD revascular-
ization with LIMA (but other arteries as well) without the
need of a sternotomy. The retraction of ribs allows manual
preparation of LIMA and performance of anastomosis under
direct visual control. This technique is called minimally
invasive direct coronary bypass – MIDACB. Its expansion
has been accelerated with the development of methods that
stabilize the heart during OPCAB, and those that facilitate
grafting of anastomosis on the beating heart. Data from
many trials show that MIDCAB has a fully comparable long
term patency of LIMA graft with the classical approach with a
sternotomy, with low perioperative morbidity, mortality and
very good mid- and long term results, comparable with
OPCAB access [50,51]. It can be performed safely even after
prior sternotomy [52] and in multivessel disease [53]. It allows
revascularization of LAD in patients with high risk of ster-
notomy or other postoperative complications, as long as the
patient is able to tolerate ventilation with one lung. The
disadvantage can be a worse control of postoperative pain
due to extensive retraction of the ribs [54].
In an effort to avoid the necessary wide retraction of ribs
during the procedure, an alternative method with the mobi-
lization of LIMA thoracoscopically, allowing to limit the width
of the thoracotomy, was developed. This technique does not
require a wide retraction of ribs, which is a must for the LIMA
preparation. This technique has been called endoscopic
atraumatic coronary bypass – EndoACAB. Perioperative and
long term results in the largest population of patients
operated this way (607) were excellent, with the graft patency
at five years being 98.5% and 95% of the patients without
cardiovascular event at five years [55]. This method requires
insufflation of left hemithorax with possible negative effects
on hemodynamic state and oxygenation of the patient. Its
usage is therefore limited in patients with pulmonary
obstruction or hypertension and in patients with severe left
ventricular dysfunction or active ischemia. It also cannot beused in patients with prior thoracic operations and in
patients with pleural adhesions [56]. The necessity of mana-
ging advanced endoscopic techniques and a related long
learning curve is probably the reason that has prevented
the widespread use of this technique.
The development of robotics in recent years has allowed
endoscopic collection of LIMA with the aid of robotic systems.
The end-anastomosis on LAD can be performed manually
using a limited thoracotomy without rib retraction. The
technique is called robotically enhanced minimally invasive
direct coronary bypass – RECAB. Trials published to date show
a high primary success rate with the patency of the graft
being 95–100%. There is low perioperative morbidity and a
high rate of patient satisfaction [57–60]. Finally, robotic
techniques allow the entire operation to be performed
endoscopically – without a sternotomy. This technique is
called totally endoscopic coronary bypass – TECAB. Initially,
the procedure was performed on a non- beating heart with
extracorporeal circulation [61,62]. This fact greatly decreased
the attractiveness of this procedure. Performance of this
procedure on a beating heart is technically challenging and
only a small number of centers have been able to perform it
to date. The only larger multicentre trial with this technique
included 111 patients. No significant differences have been
found in the efficacy when comparing this procedure to on-
and off- pump surgery. The need of conversion to classical
bypass with a sternotomy or to lateral thoracotomy was not
insignificant (28%). The success of revascularization defined
as a finding of a patent bypass during angiography or the
absence of ischemia on an electrocardiogram during exercise
testing was 97%. No attempt to compare this method with
other mini invasive techniques or classical bypass has been
made [63]. In smaller trials, the patency of LIMA has been
shown to be between 92 and 96% [64,65]. In expert hands,
even a multivessel revascularization with arterial grafts in
combination with PCI is possible [66]. This method, however,
still awaits its place in the wide range of revascularisation
procedures [67].5. Surgical revascularization outside the LAD
territory – comparison with PCI
Even with an increasing use of arterial grafts for complete
revascularization, the majority of surgical procedures still
include the use of one or more venous grafts [68]. When
compared to the revascularization with LIMA, the long- term
patency of venous grafts is substantially worse. After one
year, the incidence of bypass closure is given in the range of
12–30% [69,70]. In a large trial with more than 3000 patients,
26% of all venous grafts were occluded in 12 months and at
least one bypass was occluded or non-functional in 42% of
patients [71]. This trial represents data similar to real life. In
the five year follow-up further degradation of venous grafts
occurs, and only 60% of the grafts remain patent. After
10 years, only about half of the grafts are patent [72]. The
use of other arterial grafts has contradictory results. In some
trials, long term patency of radial artery grafts was similar to
the patency of venous grafts [73,74]. Other trials have shown
superiority of radial artery grafts [75]. A recent metaanalysis
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radial artery grafts compared to venous grafts [76]. On the
other side, long term patency of right mammary artery grafts
lies somewhere in the middle of venous grafts and LIMA
[9,72]. This is probably the reason for the improvement of
long term prognosis of patients in whom both mammary
arteries are used when compared with classical revascular-
ization with LIMA and venous grafts [77–79]. However, revas-
cularization using RIMA is not widely used for concerns with
higher incidence of infectious complications at the sternot-
omy site [80,81], even though the use of skeletonization
probably reduces this risk [82]. Considering the above, revas-
cularization of arteries other than LAD with drug eluting
stents is an acceptable alternative to venous or other types of
arterial grafts, even with the anticipated clinically significant
restenosis of approximately 10% [6].6. Hybrid myocardial revascularization in
patients with multivessel coronary artery disease
Hybrid revascularization is defined as planned combination of
surgical revascularization of LAD with percutaneous coronary
intervention on other coronary arteries. The aim is to achieve
complete or functionally adequate myocardial revascularization.
The rationality for hybrid revascularization procedures is based
on three premises, as written in the above analysis.a. The LIMA –LAD graft is probably the best revascularization
method for this artery considering the long term patency
and the resulting influence on the prognosis of the patient.b. Percutaneous coronary intervention with stent implanta-
tion on other arteries has comparable results with surgical
revascularization with venous or other arterial grafts. It
alone does not lead to impaired prognosis when compared
with surgical treatment.c. Minimally invasive surgical techniques allow for LIMA
grafting to LAD with a limited operational trauma and
with exclusion of extracorporeal circulation.
Combined minimally invasive surgery and PCI on LAD is
the reasonable outcome of the development in both fields
because it offers the best of each of the so far separated
disciplines and the smallest possible burden for the patient.
The basic requirement to this procedure is, naturally, the
technical feasibility of PCI on coronary arteries other than
LAD, with the possibility of achieving a functionally satisfac-
tory revascularization.
6.1. Indications for hybrid myocardial revascularization
HMR might be considered in patients with multiple coronary
artery disease including the proximal LAD who are indicated
for surgery, and standard surgery is for some reason con-
sidered risky [83,84]. This concerns the higher risk of ster-
notomy as well as the risks arising from the overall patient’s
condition. Previous sternotomy (reoperation), history of ster-
nal infection, previous mediastinitis, tumors affecting the
sternum (i.e.myeloma), previous thorax radiation treatment,corticosteroid therapy, severe obesity with diabetes or impor-
tant mobility impairment restricting the subsequent rehabi-
litation (crutches, wheelchair) are all conditions increasing
the complications rates for sternotomy.
The overall risk factors include advanced age, marked
frailty, multiple comorbidities, important cerebrovascular
impairment with the history of cerebral stroke or paraplegia,
serious carotid arteries disease and pulmonary illness- if it
enables single-lung ventilation. Specific cardiac risk factors
comprise poor left ventricular function, recent myocardial
infarction and difficulty to perform surgery on coronary
arteries other than LAD, for example proximal stenosis
eligible for PCI and quality of distal arteries unsuitable for a
reliable bypass anastomosis or absence of suitable conduits,
respectively (i.e. unavailability of venous grafts). This con-
cerns equally the patients who had the emergent PCI per-
formed on coronary arteries other than LAD due to acute
coronary syndrome and have LAD stenosis that is not
optimally suitable for further intervention, for example
chronic occlusion or complex lesions. Further risk factors
include vast calcifications of the aorta or mitral annulus that
increase the risk of perioperative cerebral stroke while being
manipulated. The preference of a patient demanding the less
invasive procedure even after being informed about the
bypass surgery as a standard procedure in the particular
case, should be also taken into consideration [60].
6.2. Contraindications for hybrid myocardial
revascularization
Elective hybrid revascularization is contraindicated in hemo-
dynamically unstable patients including acute myocardial
infarction and cardiogenic shock, in patients with severe
decompensated ischemic cardiomyopathy and in patients
with serious lung disease that unables ventilation of one
lung or with severe right ventricular dysfunction. Conditions
impeding the reliable performance of LIMA to LAD anasto-
mosis are history of pericarditis, previous left thoracotomy or
left pleural area surgery, extensive pleural adhesions in left
pleural space, use of, or damage to LAD in previous cardiac
surgery, unsatisfactory quality of LAD and important stenosis
or occlusion of left subclavian artery when not treated
beforehand. It is obvious that it is not suitable to consider
combined therapy in case that PCI on coronary arteries other
than LAD is not technically feasible or highly risky. Renal
dysfunction with the risk of contrast induced nephropathy
and intolerance of prolonged Clopidogrel treatment may also
play an important role in the decision- making process.
The decision whether to perform the revascularization in
classical surgical way, hybrid revascularization or PCI only, is
always multifactorial, strictly individualized and it should be
carried out in close cooperation between surgeons and
cardiologists [85].
6.3. Strategy for hybrid myocardial revascularization
Regarding the timing of the particular procedure, three basic
strategies are possible: 1. PCI first, followed by bypass surgery,
2. bypass surgery followed by PCI or 3. both performed
simultaneously throughout one integrated procedure. In case
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apart. Each of these techniques has advantages and disad-
vantages which must be taken into consideration when
planning the treatment tactics. PCI before the surgery allows
the complete surgical revascularization in case of unsuccess-
ful intervention. This is a primary method in acute coronary
syndromes except to those caused by LAD. In some cases it
allows improvement of collateral flow for LAD and thus
decreases the risk of vast ischemia during subsequent sur-
gery to this artery. In contrast, delayed mammary bypass
performance does not allow for checking it´s patency imme-
diately after surgery. However, the main disadvantage is the
conflict of using the dual antiplatelet therapy including
Clopidogrel after the PCI and the need of satisfactory hemos-
tasis after surgery. It follows that the risk of postoperative
bleeding and blood losses is increased [86–88]. Nevertheless,
most of the evidence regarding increased postoperative
bleeding after clopidogrel, stems from the trials using classi-
cal surgical techniques without use of minimally invasive
surgery. Moderate-sized trials with perioperative clopidogrel
treatment comparing the hybrid access to classical surgery
showed low bleeding complications rate and blood losses in
hybrid group [89–91]. In a group of 17 patients taking Clopi-
dogrel before surgery, there was only 1 important bleeding
event [82]. Direct comparison of bleeding complications
between groups with PCI before versus after surgery is not
available.
Another potential problem may be the termination of
heparin effect after surgery that could lead to possible stent
thrombosis. However, there are no records of acute stent
thrombosis immediately after surgery in current patients’
files. One of the effective and at the same time milder
anticoagulation possibilities during PCI as well as surgery is
use of Bivalirudin instead of Heparin. There were 3 bleeding
events requiring surgical revision in a group of 58 such
patients [60].
The largest group, where PCI is performed before surgery, is
represented by patients with acute coronary syndrome
caused by arteries other than LAD, which has to be treated
urgently. Also in case of important complex lesions outside
LAD, where risk of unsuccessful intervention is higher (type C
lesions, chronic occlusions), it is probably better to keep the
possibility of complete surgical revascularization as a backup
plan. This method must be considered when complications
arising from possible occlusion of other artery during LAD
revascularization are imminent – for instance impending
occlusion of a large vessel in the presence of critical stenosis
by possible blood pressure drop [92].
In relation to the concerns about bleeding complications
mentioned above, bypass to LAD before PCI is preferred at
most workplaces. It offers the advantage of intervention in
protected setting of revascularized LAD, which is particularly
important when severe disease of left main coronary artery is
present. It can be then safely intervened with the aim of
revascularizing the area of circumflex branches (so called
‘‘protected’’left main coronary artery) [93–95]. Mammary graft
patency may be checked during the procedure and possible
problem corrected. On the other hand, in case of failure of the
interventional procedure or serious complication, the patient
is exposed to higher risk of re-operation. It is not clear yet,what is the optimal time interval between surgery and
percutaneous intervention. Usually it takes several days,
offering enough time to correct proinflammatory and pro-
coagulation changes induced by surgery.
3. Simultaneous bypass surgery on LAD and PCI through
one integrated procedure has multiple potential advantages
[96]. Patient leaves the hospital completely revascularized
which eliminates risks and psychological burden represented
by waiting for the next procedure. Perioperative angiography
of the bypass allows the anastomosis quality evaluation and
immediate correction of a possible patency problem. On the
contrary, presence of surgical team allows aggressive coron-
ary intervention, as in case of its failure immediate surgical
resolution is possible. The advantage of an intervention in
safe conditions of total anesthesia with complete patient
monitoring is also not negligible. Yet, simultaneous proce-
dure with the necessity of subsequent dual antiplatelet
therapy opens again the question of possible bleeding com-
plications. Regarding the fact that clopidogrel is administered
after the surgery, this risk is likely lower [89,97]. One of the
disadvantages is also the necessity of an adequate equipment
of the operation theater with high-quality angiographic
system - so called hybrid rooms are currently by far not a
standard for cardiac surgery suites. Simultaneous hybrid
revascularization requires impeccable cooperation and coor-
dination of two different teams - surgical and the cardiologic
one. This often accounts for a logistical problem, disregarding
the mental barriers that may as well impede the implemen-
tation of such methods [98]. The development of hybrid
procedures in areas differing from ischemic heart disease
therapy indicates that the appropriate personnel and instru-
mental conditions for simultaneous surgical and interven-
tional procedures will be increasingly accessible [99].
6.4. Outcomes of hybrid myocardial revascularization
In spite of theoretical attractiveness of hybrid revasculariza-
tion concept, the quantity of workplaces dedicated to this
issue remains quite small and published data are scarce. First
data about hybrid revascularization performed on 6 patients
were published by Angelini et al. in 1996 [100]. The majority
of studies that followed were monocentric observational
studies comprising limited number of patients. In addition,
they are considerably heterogenous with respect to selection
criteria, hybrid procedure strategy, surgical technique, mode
of intervention, outcomes assessment and follow-up length
[60,65,82,83,88–90,92,95,101–114]. The most important stu-
dies, evaluating the postsurgical outcomes, mammary graft
patency and medium-term follow-up, are summarized in
Table 1. From presented data it is possible to say that HMR
is safe. Perioperative mortality ranged between 0 to 2%,
average mortality of all studies is 0, 3%. Medium-term graft
patency to LAD is high—92 to 100% and fully comparable to
the data from standard methods [50,51]. Target arteries
revascularization (including LAD) is 10% on average, with
bare-metal stents or simple balloon-angioplasty used in most
studies. Medium term survival without adverse events is 90%
on average. These results could be compared, for instance, to
the surgical branch of SYNTAX study, where patients with
multiple coronary artery disease were revascularized mostly
Table 1 – Summary of hybrid revascularization trials outcomes.
Author Date N Type of
procedure
PCI Hybrid revascularization strategy Follow-
up
30 days
mortality
(%)
LIMA
patency
(%)
TVR
(%)
Adverse event-
free survival (%)
Zenati [103] 1999 31 MIDCAB BMS-66%
PTCA-34%
PCI followed by MIDCAB 7%; same day-52%;
MIDCAB followed by PCI-41%
11 M 0 100 9.6 90
Lloyd [102] 1999 18 MIDCAB PTCA-52%
BMS-52%
MIDCAB, PCI thereafter-77%; simultaneous-
23%
6 M 0 100 0 89
Wittwer [104] 2000 35 MIDCAB PTCA-70%
BMS-30%
MIDCAB followed by PCI 11.5 D 0 100 NA NA
Presbitero
[106]
2001 42 MIDCAB PTCA, BMS MIDCAB followed by PCI 18 M 2 92 14 83
deCanniere
[88]
2001 20 MIDCAB PTCA-70%
BMS-30%
PCI, MIDCAB thereafter 45%; MIDCAB, PCI
thereafter 55%
24 M 0 100 5 95
Riess [95] 2002 57 Hemi-
sternotomy
PTCA-58%
BMS-48%
MIDCAB followed by PCI 24 M 0 97 16 NA
Stahl [106] 2002 54 RECAB PTCA, BMS RECAB, PCI thereafter - 65%; PCI RECAB
thereafter - 35%
11,7 M 0 100 NA 87
Cisowski
[107]
2002 50 Endo ACAB PTCA - 22%
BMS - 78%
EndoACAB followed by PCI 6–24 M 0 100 13 88
Davidavicius
[111]
2005 20 RECAB BMS-95%
DES-5%
PCI, RECAB thereafter-70%; RECAB, PCI
thereafter-30%
19 M 0 100 0 100
Katz [65] 2006 27 TECAB BMS-37%
DES-63%
PCI followed by TECAB-41%; TECAB followed
by PCI-44%; simultaneous-15%
9 M 0 100 29.6 70
Us [82] 2006 17 MIDCAB BMS Simultaneous 21 M 0 100 18 87
Gilard [109] 2007 70 Conv.
CABG
Stent in right
coronary artery
CABG followed by PCI 33 M 1.4 100 2,3 97
Kon [90] 2008 15 MIDCAB DES Simultaneous 12 M 0 100 6,7 93
Kiaii [60] 2008 58 RECAB DES-90%
BMS-10%
Simultaneous 20 M 0 93 10,3 NA
Holzhey [83] 2008 117 MIDCAB,
TECAB
BMS,
DES
MIDCAB, PCI thereafter - 48%; PCI, MIDCAB
thereafter-48%; simultaneous-4%
12 M/
5 Y
1,9 NA NA 92.5 75.5
Gao [114] 2009 10 RECAB,
TECAB
BMS-67%
DES-23%
RECAB followed by PCI 5 M 0 100 NA NA
Vassiliades
[92]
2009 95 Endo ACAB DES PCI followed by EndoACAB-6.6%; EndoACAB
followed by PCI-93.4%
12 M 0 98 5.8 90
Explanatory notes: BMS – bare metal stents, CABG – coronary artery bypass graft, DES – drug eluting stents, EndoACAB – endoscopic atraumatic coronary artery bypass, conv. ¼ conventional,
LIMA – left internal mammary artery, M – month, MIDCAB – minimally invasive direct coronary bypass, NA – not available, PCI – percutaneous coronary intervention, RECAB – robotically enhanced
coronary artery bypass, TECAB – totally endoscopic coronary artery bypass, TVR – target vessel revascularization, Y-year.
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c o r e t v a s a 5 4 ( 2 0 1 2 ) e 1 8 8 – e 2 0 1 e195with arterial grafts and where the overall mortality after 12
months was 3.5%, necessity for subsequent revascularization
5.9% and adverse events- free survival 87.6% [9]. Nonetheless,
this kind of comparison of heterogeneous patient cohorts
can be misleading. Only 3 out of all studies compared
minimally invasive hybrid revascularization outcomes to
classical surgical revascularization in comparable patient’s
cohorts, the remaining studies were observational. De Can-
niere retrospectively compared 2 groups of patients with 2-
vessel disease (20 patients in each), who underwent hybrid
revascularization (MIDCAB with subsequent balloon angio-
plasty or standard stent implantation) or classical on-pump
bypass. Postoperative complications rate was significantly
lower in hybrid group (15% vs. 65%) with lower need of blood
transfusions (0% vs. 20%). Intensive care unit stay, global
hospitalization average length and return to work time were
shorter. Three patients from hybrid group had recurrence of
angina after 6 months with subsequent PCI for restenosis or
new lesion, none of the classically operated patients required
intervention, all patients were asymptomatic after 2 years
[88]. Kon compared 15 patients with hybrid revascularization
(MIDCABþsimultaneous DES implantation) with a group of 30
similar patients treated with OPCAB. Hybrid group patients
had fewer postoperative complications (0% vs. 23%, P¼0.05),
mainly due to lower occurrence of perioperative infarction.
Myocardial ischemia, inflammatory reaction and coagulation
activation indicators were lower in hybrid group. These
patients required significantly fewer transfusions, had sub-
stantially shorter intubation length, ICU stay and overall
hospitalization length. These differences were reflected in
lower hospitalization costs. The return to work time
(p¼0.002) and time to postoperative wound pain disappear-
ance (p¼0.004) was significantly shorter in hybrid group.
After one year, adverse events were recorded in 7% of patients
from hybrid group (1 re-intervention for angina pectoris) and
23% in OPCAB group. CT angiography performed after 1 year
proved 85% bypass graft patency, while in hybrid group only
one stent failed (7%). The overall patient satisfaction with
the procedure was significantly higher in the hybrid group
[90]. Vassiliades et al. retrospectively compared group of 91
hybridly treated patients (EndoACABþsubsequent DES
implantation 93%, 7% in reverse order) with cohort of 4175
patients with OPCAB, who were operated at the same institu-
tion at the same time interval. Thirty days mortality in both
groups was 0% and 1.8%, myocardial infarction incidence
1.1% and 0.5%, target vessels revascularization 0% and 0.3%
and overall cardiovascular adverse events 1.1% a 3%—there
was no significant difference in early postoperative indica-
tors. Twelve month mortality rate for hybrid group was 1.1%
and myocardial infarction occurred in 3.3%. Five patients
in total (5.8%) required reintervention due to restenosis
(4 patients) or mammary graft restenosis (1 patient). Overall
adverse events rate was 10% and did not significantly differ
from OPCAB group [92]. Study shows that hybrid revascular-
ization is at least equally safe as standard OPCAB and in case
of DES use; the rate of subsequent revascularizations is low.
Nevertheless, these outcomes must be interpreted with
caution – it was a non-randomized study and hybrid group
patients were certainly selected, contrary to the OPCAB
group. Moreover, the number of patients in hybrid group istoo small for valid statistical comparison [115]. It is worth
to mention as well the data from Zhao et al., who perfor-
med routine angiography during standard surgery (i.e. with
sternotomy and on-pump in part of patients) in 366
patients. In 112 of them, PCI with stent implantation was
performed—either electively (in 67 patients, i.e. 60%, mostly
with the aim of loweinging the operation risk or revascular-
ization of arteries that would be problematic for bypass
anastomosis) or unplanned - due to graft patency problem
during perioperative angiography or unfeasible anastomosis
to target vessel (45 patients, i.e. 40%). Patients with hybrid
revascularization were compared to those with bypass only
(254 patients). The mortality rates in both groups were similar
(2.6 vs. 4.15%). The blood losses and reoperation rates due to
bleeding were even (3%), although 19% of patients in hybrid
group took clopidogrel before and 31% after the surgery. One
patient in hybrid group died due to acute stent thrombosis
after use of Heparin antagonist Protamine (0.9%). Patients in
hybrid group had higher levels of cardiac-specific enzymes as
a marker of perioperative damage to myocardium [116].
Although the work gives more evidence to the usefulness of
perioperative angiography than to the value of hybrid revas-
cularization, it shows that concerns regarding the postopera-
tive bleeding, caused by dual antiplatelet therapy, need not to
be great.
All remaining studies dealing with hybrid revascularization
are just observational. The largest one comprises a total of
117 patients. MIDCAB was performed in 110 of them and
TECAB in 10 patients. PCI before the surgery was carried out
in 48%, in 48% afterwards and in 4% simultaneously. Classic
to drug eluting stent ratio was not mentioned. The predicted
operative mortality was 4.3% (by EuroScore). Two patients
died (1.9%), only one of them due to cardiac event. One
patient was reoperated due to acute stent thrombosis (0.9%)
and 6 patients were surgically revised due to bleeding (5.7%).
Postoperative ventilation length was very short – 3 and5 h on
average, as well as the ICU stay length (7 and9 h). One year
survival was 92.5%, 5- year survival 84.8%, 1-year and 5-year
survival with no cardiac adverse events 85.5% and 75.5%
respectively. Twenty three patients underwent angiography
due to angina pectoris recurrence (4.3%). Authors conclude
that hybrid method is safe and the long-term outcomes are
good [83].
The largest study of hybrid revascularization with robotic-
assisted LIMA harvest (RECAB) was published by Kiaii et al.
[60]. Percutaneous intervention was performed in hybrid
theater immediately after bypass anastomosis in 58 patients
out of 60 indicated (97%), conversion to sternotomy with full
surgical revascularization was performed in 2 patients due to
arrhythmias during bypass stitching. In both procedures,
Bivalirudin was used for anticoagulation. Clopidogrel was
administered after the PCI completion. Most of the 65 stents
used were drug eluting ones (82%). Angiography immediately
after surgery proved LIMA patency in 93% of grafts. Post-
operative revision for bleeding was necessary in 3 patients
(5%), none of the patients died. ICU stay length was shorter
than 12 h in 95% of patients. The average follow-up time was
20 months, none of the patients had angina. LIMA patency
rate was 91% at coronary angiography in total of 54 patients.
In 2 patients there was unsatisfactory bypass patency and
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and once on native artery, despite the fact both patients were
asymptomatic. There was restenosis in 9 stents (15%, 7
cases), stent occlusion in 2 patients. Reintervention was
performed in 2 patients only (3.4%). Similar outcomes were
achieved by RECAB in trial on 54 patients by Stahl et al., in
which 35% of patients underwent PCI before and the rest
after the surgery. Perioperative mortality was insignificant,
69% of patients were extubated in operating theater and the
average ICU stay length was 24 h. Blood transfusion was
required in 29.6% of cases. Coronary re-angiography was
performed in 18.5% patients during follow-up (average 11
months). The mammary graft was patent in all cases; two
patients had in-stent restenosis and one patient had stent
occlusion (5.2% out of total number of implanted stents).
Reintervention was performed in one patient. Overall event-
free survival was 87% and 97% of patients had no angina
pectoris [106]. Davidavicius et al. published an interesting
concept of rationalization for hybrid revascularizations [111].
In 20 patients, who were potentially eligible for hybrid
revascularization (RECAB), functional evaluation of stenosis
on arteries excluding LAD was performed using the fractional
flow reserve – FFR. In 14 patients it was performed before
robotic-assisted procedure, in 6 of them thereafter. PCI was
performed only in case of hemodynamically significant ste-
nosis (FFR value lower than 0.80) – in 14 patients, all of
whome had a standard stent implanted (95%). The interven-
tion was postponed in 6 patients who did not have a
hemodynamically significant stenosis. The robotic-assisted
bypass to LAD was complication-free, all arterial grafts were
patent at postoperative angiography. At medium-term check-
up after 19 months on average, none of the patients had
cardiovascular adverse event and their stress test was nega-
tive. Only one patient underwent coronary re-angiography
due to chest pain with angiographically and functionally
non-significant in-stent restenosis (FFR higher than 0.80).
FFR measurement enables restriction of PCI use only to
lesions causing ischemia and thus lowering the risk of the
procedure itself as well as the risk of significant restenosis.
Postponing the intervention for lesions that are not hemody-
namically significant is equally safe or possibly safer than
their intervention [117,118].
The experience with totally endoscopic robotic-assisted
coronary revascularization (TECAB) associated with PCI is
limited. Katz et al. published a set of 27 patients where 41%
had PCI before and 44% after robotic surgery, DES were used
in 63% of cases. Only 1 patient had symptoms of myocardial
infarction in perioperative period, no other important event
occured. All patients underwent coronary angiography 3
months later, 1 patient had graft stenosis in the anastomosis
(3.7%), which was treated by angioplasty. Seven patients in
total had PCI for in-stent restenosis during further follow-up
period (4 patients) or new lesion on previously intervened
artery (3 patients), therefore the total number of subsequent
revascularizations was unusually high (29%). Five of these
lesions were detected by coronary angiography as early as
3 months after revascularization [65].
Results of these observational and comparative studies
show that minimally invasive hybrid revascularization pro-
cedures in patients with multivessel coronary artery diseasecarry minimal perioperative mortality risk, low morbidity and
do not increase the risk of postoperative bleeding. The med-
ium-term cardiovascular adverse events rate including the
necessity of further revascularization is acceptable. The advan-
tage they offer in comparison to classical surgical revascular-
ization is indeed faster rehabilitation and patient’s return to
normal life. Nevertheless, available studies do not allow any
definite conclusions neither about the overall effectivity on
hard clinical endpoints (mortality, myocardial infarction) when
compared to standard surgery methods, nor about the long-
term effects. Patient cohorts were highly selected and they
represent just a small proportion of surgical interventions even
at sites dealing intensely with minimally invasive and hybrid
procedures. The share of hybrid procedures on total number of
revascularization interventions in the work of Vassiliades et al.
was only 2.1% [92]. HRM share on all minimally invasive
revascularization procedures at a different institution was
6.4% [83]. Selection pointed towards the patients who had
relatively benign coronary lesions designated for PCI. This
reflected the fact that in majority of hybrid procedures the
percutaneous intervention was performed on only one addi-
tional coronary artery. The question is whether the outcomes
would be the same if patient selection was less rigorous, i.e. if
the selection comprised also patients with multiple lesions
outside LAD territory, as we observe in real- life patients
indicated for classical surgery. Would it be possible to improve
the outcomes of the interventional branch of SYNTAX trial,
where coronary disease was complex and required on average
implantation of 4, 6 stents [9]? Similarly, could the outcomes of
patients, considered to be treatable only by surgery who were
included into the surgical register of this trial, be improve this
way? Could the outcomes of specific subgroups improve – for
example in patients with left main coronary artery disease? On
the other hand, for many cardiologists today the only limita-
tion to adequate interventional revascularization is chronic
LAD occlusion which is impossible to cross. In many patients
indicated for hybrid revascularization, LAD or left main cor-
onary artery were patent, therefore the intervention with
modern instruments was not entirely unfeasible. Up to date,
there is no comparison of hybrid revascularization to percuta-
neous intervention available in such patients.
The only way to assess the real clinical value of hybrid
revascularization in comparison to classical surgery (or
percutaneous interventional treatment) is to provide an
adequately large randomized trial which would monitor the
classical hard‘‘ endpoints such as perioperative and post-
operative mortality indicators and overall patient quality of
life through short-term and long -term follow-up. These trial
should include low-risk patients so that the hybrid proce-
dures could be introduced into the common clinical practice.
An equally based trial should be performed, comparing the
hybrid revascularization to PCI to answer the question
whether it is clinically beneficial to expand the hybrid
procedure indications to patients with less severe LAD dis-
ease. Logistic and organizational obstacles to such trials are
immense, though, starting with surgical technique selection
(MIDCAB, EndoACAB, RECAB, TECAB?), continuing with the
right procedure-timing (prior to, after-, simultaneously, when
and in whom?), ending up with high financial requirements,
considering the necessity of randomizing thousands of
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spreading of hybrid revascularization methods and organiza-
tion of necessary trials is probably the need of a narrow
cooperation between so far separated specialties represented
by cardiac surgeons and cardiologists, who would have to
discuss the particular patient together and assess the optimal
revascularization scenario for the particular coronary anat-
omy, clinical situation and socioeconomic status, such as it
was carried out in SYNTAX trial mentioned above [119].
Meanwhile, the use of hybrid revascularization procedures
will probably be limited to highly selected patients who for
any reason cannot (or do not wish to) undergo one of the
established revascularization methods.Conclusion
Modern medicine offers many options of treatment to
patients with ischemic heart disease and multiple coronary
lesions. The treatment possibilities include conventional
aortocoronary bypass using the extracorporeal circulation,
OPCAB on the beating heart, multiple PCI with standard or
drug eluting stents or hybrid revascularization procedures
comprising minimally invasive surgical techniques combined
with percutaneous intervention.
The population ageing and growing number of polymorbid
patients requiring revascularization determines increasing
need of individualized approach and necessity of tailoring
the treatment to each of them, aiming to reach the optimal
ratio of clinical efficacy and safety of the particular proce-
dure. Hybrid revascularization using minimally invasive sur-
gical techniques combined with PCI offer to a part of patients
an advantage of optimal revascularization of the most
important artery of the heart, together with adequate myo-
cardial revascularization in a relatively delicate way. Indeed,
to patients with high operative risk of standard surgery, it
offers an alternative which should be considered carefully.
The results of published hybrid revascularization trials show
low perioperative mortality, morbidity and quick rehabilita-
tion as well as very acceptable medium-term outcomes.
Nevertheless, present studies are mostly retrospective and
observational, carried out on quite small number of patients
and therefore do not allow a clear short or medium-term
comparison of hybrid to standard techniques. Long-term
outcomes are not available at all. Larger HRM penetration
into clinical practice is limited by technical demands of
certain techniques requiring specialized equipment as well
as by inertia of established decision-making schemes, lack of
cooperation and sometimes even competition between spe-
cialists of two so far separated domains.
Questions concerning the clinical merit of particular meth-
ods and use of hybrid revascularization techniques in treat-
ment of patients with multiple coronary artery lesions can be
answered only by randomized and adequately large prospec-
tive clinical studies. Meanwhile, the decision for hybrid
revascularization in a particular patient will be based more
on experience and possibilities of specific site than on
evidence-based medicine. Now it is time to answer the
challenge of providing such evidence.r e f e r e n c e s
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